CpG Island Methylation Patterns in Relapsing-Remitting Multiple Sclerosis

Area of Science:

• Epigenetics
• Neuroimmunology
• Genetics

Background:

• Aberrant DNA methylation in promoter regions is implicated in multiple sclerosis (MS) pathogenesis.
• Understanding methylation patterns is crucial for identifying potential biomarkers in MS.

Purpose of the Study:

• To investigate the DNA methylation status of eight genes in relapsing-remitting MS patients.
• To determine if specific methylation patterns can distinguish MS patients from healthy controls and differentiate disease states.

Main Methods:

• Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) was employed.
• Analyzed 31 CpG islands across eight genes in 66 MS patients and 33 healthy controls.
• Utilized Receiver Operating Characteristic (ROC) curves to establish diagnostic cut-offs.

Main Results:

• Significant differences in methylation positivity for RUNX3 and CDKN2A were observed between MS patients and controls.
• Maximum methylation levels in RUNX3, CDKN2A, SOCS1, and NEUROG1 genes differed significantly between groups.
• Specific methylation cut-offs for RUNX3 (2%) and CDKN2A (3%) effectively distinguished MS patients from healthy individuals.

Conclusions:

• Methylation patterns of RUNX3 and CDKN2A show potential as biomarkers to discriminate between MS patients and healthy controls.
• No significant methylation differences were found between MS patients in relapse versus remission, suggesting these patterns do not reflect disease activity.